Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
10 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Boehringer Ingelheim Veterinary Medicine Belgium NV from Evergem, company number BE0842800336, closed financial year 2025 with a result of € 486,745 after tax. Compared with financial year 2024, the result moved from € 752,127 to € 486,745. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.
€ 5.6 million
▲ 10% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 486,745
▼ 35% vs 2024
Profit after tax over the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 1.6 million.
People and assets in 2025
17.9
▲ 1.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 2 million
▲ 15% vs 2024
€ 109,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 2,163
▼ 63% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 511,993
▲ 9% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 63 days on average.
€ 429,350
▲ 24% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 392,000 | € 223,782 | € 0 | - | |
| Profit after taxes | € 139,352 | € 649,392 | € 752,127 | € 486,745 | ▼ 35% |
| Equity | € 3,675,840 | € 4,325,232 | € 5,077,359 | € 5,564,104 | ▲ 10% |
| Total debts | € 1,522,336 | € 1,048,077 | € 815,006 | € 941,343 | ▲ 16% |
| Retained profit | € -319,691 | € 329,701 | € 1,081,828 | € 1,568,573 | ▲ 45% |
| Balance sheet total | € 5,198,176 | € 5,373,309 | € 5,892,365 | € 6,505,447 | ▲ 10% |
| Employees (FTE) | 14.8 | 16.9 | 16.8 | 17.9 | ▲ 1.1 |
Key figures of Boehringer Ingelheim Veterinary Medicine Belgium NV, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Boehringer Ingelheim Veterinary Medicine Belgium NV?
What happened at Boehringer Ingelheim Veterinary Medicine Belgium NV in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Carla Ramon stepped down as director. NBB
- Friedrich Kaess stepped down as director. NBB
- Lukas Hauschild stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 486,745 (▼ 35% vs 2024). Source: NBB ↗
- Christoph Tautphäus stepped down as director. NBB
- Lukas Hauschild became a director. NBB
- Larisa Nurkanovic stepped down as director. NBB
- Silke Seeber stepped down as director. NBB
In short
From € 139,352 profit in 2022 to € 486,745 profit in 2025.
Paid € 289 in corporate taxes since 2022.
Best year ever: 2024, with € 752,127 profit.
Pays suppliers within 63 days on average.
A new publication or filing at Boehringer Ingelheim Veterinary Medicine Belgium NV? We notify you, reason included.
Follow Boehringer Ingelheim Veterinary Medicine Belgium NVDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Boehringer Ingelheim Vetmedica GmbH (100%).
Directors
According to the 2025 annual accounts
Silke Seeber
Managing director
since 2023 · until 2026
Sebastian Guijarro
Director
since 2024 · until 2025
Friedrich Kaess
Managing director
since 2026 · until 2029
Carla Ramon
Director
Also active at: Boehringer Ingelheim Animal Health Belgium SA, BOEHRINGER INGELHEIM CENTRE SA
since 2025 · until 2030
since 2024 · until 2025
since 2025 · until 2026
Christoph Tautphäus
Director
Also active at: Boehringer Ingelheim SComm, BOEHRINGER INGELHEIM CENTRE SA
since 2025 · until 2026
Lukas Hauschild
Director
since 2026 · until 2029
Shareholders
Boehringer Ingelheim Vetmedica GmbH
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Noorwegenstraat 4
9940 Evergem
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 10 companies are registered at this address.
All companies at this address →LABORATORIUM M. NUYTINCK
€ 24.5 million revenue · 2025
LABO VOOR KLINISCHE BIOLOGIE
€ 3.6 million gross margin · 2025
POST VERBA VERBERA
€ 4.5 million revenue · 2025
ANABIOTEC
€ 9 million gross margin · 2025
Group Nuytinck
+5 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0842.800.336
- VAT number
- BE 0842.800.336
- Registered office
- Noorwegenstraat 4, 9940 Evergem
- Names & denominations
- Boehringer Ingelheim Veterinary Medicine Belgium NV · BIVMB
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 17 January 2012
- Peppol
- Active · Active since 30 Mar 2026
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Diensten in verband met de verzorging van huisdieren, muv veterinaire diensten
Vervaardiging van overige farmaceutische producten
Vervaardiging van geneesmiddelen
Vervaardiging van farmaceutische grondstoffen
Diensten in verband met de verzorging van huisdieren, m.u.v. veterinaire diensten
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied